Guidelines of the Brazilian Association of Studies on Alcohol and Other Drugs (ABEAD) for diagnoses and treatment of psychiatric comorbidity with alcohol and other drugs dependence;Diretrizes da Associação Brasileira de Estudos do Álcool e outras Drogas (ABEAD) para o diagnóstico e tratamento de comorbidades psiquiátricas e dependência de álcool e outras substâncias

Revista Brasileira de Psiquiatria

Volumn 28, Issue 2, 2006, Pages 142-148

  Zaleski, Marcos ^a,b,i   Laranjeira, Ronaldo Ramos ^c   Roselli Marques, Ana Cecília Petta ^c   Ratto, Lílian ^d   Romano, Marcos ^c   Palhares Alves, Hamer Nastasy ^c   De Macedo Soares, Márcia Britto ^e   Abelardino, Valter ^f   Kessler, Félix ^g   Brasiliano, Sílvia ^e   Nicastri, Sérgio ^h   Hochgraf, Patrícia Brunferntrinker ^e   Gigliotti, Analice De Paula ^i,j   Lemos, Tadeu ^a,b  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

^b Instituto de Cardiologia de Santa Catarina   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d Santa Casa de Misericordia de Sao Paulo   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f Centro de Atendimento Médico e Social CAMPS Clínica Vitao   (Brazil)

^g HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^h HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

ⁱ Santa Casa do Rio de Janeiro ^*  (Brazil)

^j GAMA FILHO UNIVERSITY   (Brazil)

more..

Author keywords

Combined modality therapy; Comorbidity; Diagnosis; Practice guidelines; Substance related disorders

Indexed keywords

BENZODIAZEPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ALCOHOLISM; BORDERLINE STATE; CLINICAL TRIAL; COMORBIDITY; DELIRIUM; DRUG DEPENDENCE; DRUG TOLERANCE; HEALTH CARE ORGANIZATION; HUMAN; MENTAL DISEASE; PRACTICE GUIDELINE; PSYCHOPATHY; REVIEW;

BRAZIL; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); HUMANS; MENTAL DISORDERS; SOCIETIES, SCIENTIFIC; SUBSTANCE-RELATED DISORDERS;

EID: 33746169842     PISSN: 15164446     EISSN: 15164446     Source Type: Journal    
DOI: 10.1590/S1516-44462006000200013     Document Type: Review

References (79)

1. Ross HE, Glaser FB, Germanson T. The prevalence of psychiatric disorders in patients with alcohol and other drug problems. Arch Gen Psychiatry. 1988;45(11):1023-31.
2. Watkins TR, Lewellen A, Barret M. Issues and problems with dual diagnosis. In: Dual diagnosis: An integrated approach to treatment. Thousand Oaks, Ca: Sage; 2001. p. 11-24.
3. Drake RE, Osher FC, Wallach MA. Alcohol use and abuse in schizophrenia. A prospective community study. J Nerv Ment Dis. 1989;177(7):408-14.
4. Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. Schizoph Res. 1996;20(1-2):145-51.
5. Ziedonis D, Brady K. Dual diagnosis in primary care. Detecting and treating both the addiction and the mental illness. Med Clin North Am. 1997;81(4):1017-36.
6. Regier DA, Boyd JH, Burk JD Jr, Rae DS, Myers JK, Kramer M, George LK, Robins LN, Karno M, Locke BZ. One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites. Arch Gen Psychiatry. 1988;45(11):977-86.
7. Drake RE, Wallach MA. Moderate drinking among people with severe mental illness. Hosp Community Psychiatry. 1993;44(8):780-1.
8. el-Guebaly N. Substance abuse and mental disorders: the dual diagnostic concept. Can J Psychiatry. 1990;35(3):261-7.
9. Hersh DF, Modesto-Lowe V. Drug abuse and mood disorders. In: Henry BK, Bruce J, Rounsaville MD, editors. Dual Diagnosis and treatment: Substance Abuse and Comorbid Medical and Psychiatric Disorders. New York: Marcel Dekker; 1998. p. 177-201.
10. Lotufo-Neto F, Gentil, V. Alcoholism and phobic anxiety - a clinical-demographic comparison. Addiction. 1994;89(4):447-53.
11. Cox BJ, Norton GR, Swinson RP, Endler NS. Substance abuse and panic-related anxiety: a critical review. Behav Res Ther. 1990;28(5):385-93.
12. Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. Am J Psychiatry. 1990;147(6):685-95.
13. Kranzler HR, Mason B Modesto-Lowe V. Prevalence, diagnosis, and treatment of comorbid mood disorders and alcoholism. In: Kranzler HR, Rounsaville B, eds. Dual Diagnosis and Treatment. New York: Marcel Dekker, Inc; 1998. p. 107-36.
14. Hitzemann R. Animal models of psychiatric disorders and their relevance to alcoholism. Alcohol Res Health. 2000;24(3):149-58.
15. Schuckit MA, Monteiro MG. Alcoholism, anxiety and depression. Br J Addiction. 1988;83(12):1373-80.
16. Latimer WW, Stone AL, Voight A, Winters KC, August GJ. Gender differences in psychiatric comorbidity among adolescents with substance use disorders. Exp Clin Psychopharmacol. 2002;10(3):310-5.
17. Biederman J, Faraone SV, Spencer T, Wilens T, Norman D, Lapey KA, Mick E, Lehman BK, Doyle A. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150(12):1792-8.
18. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152(11):1652-8.
19. Armstrong TD, Costello EJ. Community studies on adolescent substance use, abuse, or dependence and psychiatric comorbidity. J Consult Clin Psychol. 2002;70(6):1224-39.
20. King AC, Bernardy NC, Hauner K. Stressful events, personality, and mood disturbance: gender differences in alcoholics and problem drinkers. Addict Behav. 2003;28(1):171-87.
21. Brienza RS, Stein MD. Alcohol use disorders in primary care: do gender-specific differences exist? J Gen Intern Med. 2002;17(5):387-97.
22. Johnson ME, Yep MJ, Brems C, Theno SA, Fisher DG. Relationship among gender, depression, and needle sharing in a sample of injection drug users. Psychol Addict Behav. 2002;16(4):338-41.
23. Hendrick V, Altshuler LL, Gitlin MJ, Delrahim S, Hammen C. Gender and bipolar illness. J Clin Psychiatry. 2000;61(5):393-6; quiz 397.
24. Rounsaville BJ, Kranzler HR, Ball S, Tenne H, Poling J, Trifflemann E. Personality disorders in substance abusers: relation to substance use. J Nerv Ment Dis. 1998;186(2):87-95.
25. Hatzitaskos P, Soldatos CR, Kokkevi A, Stefanis CN. Substance abuse patterns and their association with psychopathology and type of hostility in male patients with borderline and antisocial personality disorder. Compr Psychiatry. 1999;40(4):278-82.
26. Regier DA, Myers JK, Kramer M, Robins LN, Blazer DG, Hough RL, Eaton WW, Locke BZ. The NIMH Epidemiological Catchment Area Program. Historical context, major objectives, and study population characteristics. Arch Gen Psychiatry. 1984;41(10):934-41.
27. Regier DA, Farmer ME, Rae DG, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchment Area (ECA). Study. JAMA. 1990;264(19):2511-18.
28. Holderness CC, Brooks-Gunn J, Warren MP. Co-morbidity of eating disorders and substance abuse. Int J Eating Disorder. 1994;16(1):1-34. Review.
29. Negrao AB, Cordas TA. Clinical characteristics and course of anorexia nervosa in Latin America, a Brazilian sample. Psychiatry Res. 1996;62(1):17-21.
30. Bulik CM, Sullivan PF, Carter FA, Joyce PR. Lifetime comorbidity of alcohol dependence in women with bulimia nervosa. Addict Behav. 1997;22(4):437-46.
31. Hurt RD, Offord KP, Croghan IT, Gomez-Dahl L, Kottke TE, Morse RM, Melton LJ 3rd. Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. JAMA. 1996;275(14): 1097-103. Erratum: JAMA. 1996;276(10):784.
32. Glassman AH, Helzer JE, Covey LS, Cottler LB, Steiner F, Tipp JE, Johnson J. Smoking cessation and major depression. JAMA. 1990;264(12):1546-49.
33. Cuffel BJ. Prevalence estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment Dis. 1992;180(9):589-92, discussion 593-6. Review.
34. Bartels SJ, Drake RE, Wallach MA. Long-term course of substance use disorders among patients with severe mental illness. Psychiatr Serv. 1995;46(3):248-51.
35. Salloum IM, Moss HB, Daley DC. Substance abuse and schizophrenia: impediments to optimal care. Am J Drug Alcohol Abuse. 1991;17(3):321-36.
36. Patrick DL, Bergner M. Measurement of health status in the 1990's. Ann Rev Public Health. 1990;11:165-83.
37. Chander G, McCaul ME. Co-occurring psychiatric disorders in women with addictions. Obstet Gynecol Clin North Am. 2003;30(3):469-81.
38. Babor TF, de la Fuente JR, Saunders J, Grant M. AUDIT: the alcohol use disorders identification test: guidelines for use in primary health care. Geneva: World Health Organization; 1992.
39. Prochaska JO, Di Clemente CC. Toward a comprehensive model of change. In: Miller WR, Heather N, eds. Treating addictive behaviors: processes of change. New York: Plenum; 1986. p. 3-27.
40. Osher FC, Kofoed LL. Treatment of patients with psychiatric and psychoactive substance abuse disorders. Hosp Community Psychiatry. 1989;40(10):1025-30.
41. Ryglewicz H, Pepper B. The dual disorder client: mental disorder and substance use. In: Cooper S, Lentner TH, eds. Innovations in community mental health. Sarasota, FL: Professional Research Press; 1992. p. 270-90.
42. Ries RK, Ellingson T. A pilot assessment at one month of 17 dual diagnoses patients. Hosp Community Psychiatry. 1990;41(11):1230-3.
43. Drake RE, Wallach MA. Moderate drinking among people with severe mental illness. Hosp Community Psychiatry. 1993;44(8):780-2.
44. Johnson S. Dual diagnosis of severe mental ilness and substance misuse: a case for specialist services? Br J Psychiatry. 1990;171:205-8.
45. Jerrel JM, Ridgely MS. Comparative effectiveness of three approaches to serving people whit severe mental illness and substance abuse disorders. J Nerv Ment Dis. 1995;183(9):566-76.
46. Menezes PR. The outcome of schizophrenia and related psychoses after hospitalization: a prospective study in São Paulo, Brazil [thesis]. London: University of London; 1995.
47. Ratto LRC. Prevalência da comorbilidade entre transtornos mentais graves e transtornos devidos ao uso de substâncias psicoativas em São Paulo, Brasil [dissertação]. São Paulo: Faculdade de Medicina da Universidade de São Paulo; 2000. p. 74.
48. Heckert U, Andrade L, Alves MJ, Martins C. Lifetime prevalence of mental disorders among homeless people in a southeast city in Brazil. Eur Arch Psychiatry Clin Neurosci. 1999;249(3):150-5.
49. Links PS. Developing effective services for patients with personality disorders. Can J Psychiatry. 1998;43(3):251-9.
50. Beck AT, Wright FD, Newman CF, Liese BS. Cognitive therapy of substance abuse. New York: Guilford Press; 1993. p. 340.
51. Reich JH, Vasile RG. Effect of personality disorders on the treatment outcome of Axis I conditions: an update. J Nerv Ment Dis. 1993;181(8):475-84. Review.
52. Strand, JG, Benjamin LS. Resistance to change in individuals with personality disorders. Curr Opin Psychiatry. 1997;10(2):132-5.
53. Fleck MP, Lafer B, Sougey EB, Del Porto JA, Brasil MA, Juruena MF. Diretrizes da Associação Médica Brasileira para o tratamento da depressão (versão integral). Rev Bras Psiquiatr. 2003;25(2):114-22.
54. Schuckit MA. Drug and alcohol abuse. 4th ed. New York: Plenum Publishing; 1995.
55. Marlatt GA, Gordon JR. Relapse prevention. New York: Guilford; 1985.
56. Cornelius JR, Bukstein O, Salloum I, Clark D. Alcohol and psychiatric comorbidity. Recent Dev Alcohol. 2003;16:361-74.
57. Bradizza CM, Stasiewicz PR. Integrating substance abuse treatment for the seriously mentally ill into inpatient psychiatric treatment. J Subst Abuse Treat. 1997;14(2):103-11.
58. Ries RK, Russo J, Wingerson D, Snowden M, Comtois KA, Srebnik D, Roy-Byrne P. Shorter hospital stays and more rapid improvement among patients with schizophrenia and substance disorders. Psychiatr Serv. 2000;51(2):210-5.
59. el-Guebaly N, Hodgins DC, Armstrong S, Addington J. Methodological and clinical challenges in evaluating treatment outcome of substance-related disorders and comorbidity. Can J Psychiatry. 1999;44(3):264-70.
60. Yager J, Andersen A, Devlin M, Egger H, Herzog D, Mitchell J, Powers P, Yates A, Zerbe K, eds. Practice guidelines for the treatment of patients with eating disorders. 2nd ed. Washington DC: American Psychiatric Association Press; 2000.
61. Hughes JR. Treatment of smoking cessation in smokers with past alcohol/drug problems. J Subst Abuse Treat. 1993;10(2):182-7.
62. Stuyt EB. Recovery rates after treatment for alcohol/drug dependence. Tobacco users vs. non-tobacco users. Am J Addict. 1997;6(2):159-67.
63. Bien TH, Burge R. Smoking and drinking: a review of the literature. Int J Addict. 1990;25(12):1429-54.
64. Farren CK, O'Malley SS. Occurrence and management of depression in the context of naltrexone treatment of alcoholism. Am J Psychiatry. 1999;156(8):1258-62.
65. Tedeschi M. Naltrexone and acamprosate. Using new drugs for alcohol dependence. Aust Fam Physician. 2001;30(5):447-50.
66. Busto U, Sellers EM, Naranjo CA, Cappell HD, Sanchez-Craig M, Simpkins J. Patterns of benzodiazepine abuse and dependence. Br J Addict. 1986;81(1):87-94.
67. Ellis P, Carney MW. Benzodiazepines abuse and management of anxiety in the community. Int J Addict. 1988;23(10):1083-90.
68. Kranzler HR, Burleson JA, Del Boca FK, Babor TF, Korner P, Brown J, Bohn MJ. Buspirone reatment of anxious alcoholics. A placebocontrolled trial. Arch Gen Psychiatry. 1994;51(9):720-31.
69. Schubiner H, Tzelepis A, Isaacson JH, Warbasse LH 3rd, Zacharek M, Musial J. The dual diagnosis of attention-deficit/hyperactivity disorder and substance abuse: case reports and literature review. J Clin Psychiatry. 1995;56(4):146-50.
70. Volkow ND, Fowler JS, Wang GJ, Ding YS, Gatley SJ. Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur Neuropsychopharmacol. 2002;12(6):557-66.
71. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. J Addict Dis. 2002;21(2):1-16.
72. Riggs PD, Leon SL, Mikulich SK, Pottle LC. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry. 1998;37(12):1271-8.
73. Anderson IM, Nutt DJ, Deakin JF. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology. J Psychopharmacol. 2000;14(1):3-20.
74. Rossinfosse C, Wauthy J, Bertrand J. SSRI antidepressants and alcoholism.Rev Med Liege. 2000;55(11):1003-10.
75. Nunes EV, McGrath PJ, Wager S, Quitkin FM. Lithium treatment for cocaine abuser with bipolar spectrum disorders. Am J Psychiatry. 1990;147(5):655-7.
76. Sonne SC, Brady KT. Substance abuse and bipolar comorbidity. Psychiat Clin North Am. 1999;22:609-27. ix. Review.
77. Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, Paris L. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003;28(10):1882-8.
78. Potvin S, Stip E, Roy JY. Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses. Int Clin Psychopharmacol. 2003;18(3):121-32.
79. Ziedonis D, Brady K. Dual diagnosis in primary care. Detecting and treating both the addiction and the mental illness. Med Clin America. 1997;81(4):1017-36.